Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Authors

Mark N. Stein

Columbia University Medical Center, New York, NY

Mark N. Stein , Jingsong Zhang , William Kevin Kelly , David R Wise , Kai Tsao , Benedito A. Carneiro , Gerald Steven Falchook , Furong Sun , Shilpa Govindraj , Jennifer S Sims , Min Zhu , Frank A. Seebach , Israel Lowy , Pradeep Thanigaimani , Sabina Sandigursky , Elizabeth Miller

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03972657

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 154)

DOI

10.1200/JCO.2023.41.6_suppl.154

Abstract #

154

Poster Bd #

E14

Abstract Disclosures

FEATURED

Preliminary results from a phase 1/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Authors

Mark N. Stein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.